Lipid nanoparticle delivery compositions for therapeutic agents
Summary
USPTO granted ModernaTX patent US12595226B2 for novel lipid nanoparticles and compositions for intracellular delivery of therapeutic agents. The patent covers carbonate-containing lipid compounds and compositions for delivering therapeutic and prophylactic agents such as RNA to mammalian cells. The patent contains 25 claims and names five inventors.
What changed
USPTO granted patent US12595226B2 to ModernaTX, Inc. on April 7, 2026, covering novel lipid compounds and lipid nanoparticle (LNP) compositions for intracellular delivery of therapeutic agents. The patent describes empty or loaded LNPs including novel lipids, phospholipids, structural lipids, and PEG lipids, useful for delivering RNA and other therapeutics to regulate polypeptide, protein, or gene expression.
Pharmaceutical companies and biotechnology firms engaged in nucleic acid delivery, mRNA therapeutics, or gene therapy development should review this patent to assess potential freedom-to-operate implications. The broad claims covering LNP compositions with carbonate-containing lipids may affect R&D programs in the drug delivery space.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
Grant US12595226B2 Kind: B2 Apr 07, 2026
Assignee
ModernaTX, Inc.
Inventors
Kerry E. Benenato, Souvik Biswas, Mark Cornebise, Edward Hennessy, Ellalahewage S. Kumarasinghe
Abstract
The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
CPC Classifications
C07C 217/08 A61K 9/1272
Filing Date
2020-09-18
Application No.
17761984
Claims
25
Related changes
Get daily alerts for ChangeBridge: Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Grants - Pharma (A61K) publishes new changes.